Moderna CEO sees personalized cancer vaccine as potential best-seller - MedWatch
Moderna's CEO publicly positioned the company's personalized cancer vaccine as a potential best-seller, per MedWatch. The article is paywalled, so no additional trial or commercial detail is available from this item. The signal for the sector is the framing itself: a leading mRNA player discussing personalized neoantigen vaccines in best-seller terms supports the commercial case for the category — individualized products at scale — beyond clinical proof-of-concept, and is relevant context for how investors should weight platform bets across the space.